Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04136275 · ClinicalTrials.gov registry record · Phase 1
CAR-37 T Cells in Hematologic Malignancies
A Phase 1 study, sponsored by Marcela V. Maus, M.D.,Ph.D..
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04136275: Completed Phase 1 study, sponsored by Marcela V. Maus, M.D.,Ph.D..
NCT04136275 is a Phase 1 study that has completed, run by Marcela V. Maus, M.D.,Ph.D.. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04136275, a Phase 1 study, has completed, sponsored by Marcela V. Maus, M.D.,Ph.D..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This research study is studying Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) for treating people with relapsed or refractory CD37+ hematologic malignancies and to understand the side effects when treated with CAR-37 T Cells. \- Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) is an investigational treatment
Interventions
- BIOLOGICAL CAR-37 T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-06-19 |
| Est. Completion | 2024-03-01 |
| Phase | Phase 1 |
What the finished NCT04136275 record still lists
NCT04136275 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which CAR-37 T cells is the first listed.
NCT04136275 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04136275 about?
NCT04136275 is a clinical study titled "CAR-37 T Cells in Hematologic Malignancies". This research study is studying Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) for treating people with relapsed or refractory CD37+ hematologic malignancies and to understand the side effects when treated with CAR-37 T Cells. \- Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cel...
What is the current status of trial NCT04136275?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2020-06-19. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT04136275?
The interventions under investigation include: CAR-37 T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04136275?
This trial is sponsored by Marcela V. Maus, M.D.,Ph.D., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04136275's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI